• The INTERCEPT® Blood System for Platelets,
    Pathogen Reduction System

    USA Region

  • The INTERCEPT® Blood System for Platelets

    Transfusion-Ready Platelets for Patients

  • The INTERCEPT® Blood System for Platelets

    Reduced Risk of Bacterial Contamination
    and Sepsis

  • 1
  • 2
  • 3

*Certain non-enveloped viruses (e.g., HAV, HEV, B19 and poliovirus) and Bacillus cereus spores have demonstrated resistance to the INTERCEPT process.

  1. Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion: Guidance for Industry, September 2019..
  2. Kleinman S et al. Transfusion 2013;53:1603-1618.
  3. Stramer SL, Hollinger FB, et al. Transfusion 2009;49(Suppl 2):1S-29S.
  4. Rasongles P, et al. Transfusion 2009;49:1083-91.
  5. Succo T et al. Euro Surveill. 2016 May 26;21(21).
  6. Gjenero-Margan I et al. Euro Surveill. 2010 Sep 2;15(35).
  7. Danis K et al. Euro Surveill. 2011 Aug 25;16(34).
  8. Barzon L et al. Euro Surveill. 2009 Aug 6;14(31).
  9. Schmidt M et al. Transfus Med Hemother 2014;41:10-17.
  10.  "FDA. Revised Recommendations for Reducing the Risk of Zika Virus Transmission by Blood and Blood Components. FDA Guidance for Industry July 2018.
  11. ABC News; “The Nation Has a Major Blood Shortage,” September 19, 2018.
  12. The INTERCEPT Blood System for Platelets Package Insert, Cerus Corporation; July 17, 2018.
  • 1
  • 2